Lushang Freda Pharmaceutical Co (SHSE:600223) Cash per Share : ¥3.19 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Lushang Freda Pharmaceutical Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Lushang Freda Pharmaceutical Co's Cash per Share for the quarter that ended in Mar. 2024 was ¥3.19.

Lushang Freda Pharmaceutical Co Cash per Share Historical Data

The historical data trend for Lushang Freda Pharmaceutical Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lushang Freda Pharmaceutical Co Cash per Share Chart

Lushang Freda Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

3.63

5.03

5.09

4.25

1.71

Lushang Freda Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															3.38	1.80	1.55	1.71	3.19

Lushang Freda Pharmaceutical Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Lushang Freda Pharmaceutical Co's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	1733.585	/	1,017
	=	1.71

Lushang Freda Pharmaceutical Co's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	3241.171	/	1,017
	=	3.19

Lushang Freda Pharmaceutical Co (SHSE:600223) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Lushang Freda Pharmaceutical Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Lushang Freda Pharmaceutical Co Ltd (SHSE:600223) » Definitions » Cash per Share

Traded in Other Exchanges

N/A

Address

No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN

Website

http://www.lshzy.com.cn

Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.

Executives

Li Hang	senior management
Yin Wei	Directors, senior managers
Shao Zhao Wei	senior management
Wang Zhong Wu	senior management
Dong Hong Lin	Director
Zhou Hong Bo	senior management
Li Lu	senior management
Liu Zeng Wei	senior management
Zhang Quan Li	senior management
Xu Tao	senior management
Ju Hai Bo	Director
Zhao Xi Liang	Director
Pi Xi Cai	Supervisors

Lushang Freda Pharmaceutical Co (SHSE:600223) Headlines

No Headlines